HANNOVERSCHE KINDERHEILANSTALT

Their core work

Hannoversche Kinderheilanstalt (HKA) is a private pediatric hospital in Hannover, Germany, specializing in clinical care and research focused on type 1 diabetes in children and adolescents. Within the INNODIA consortium, HKA functions as a clinical trial site, contributing patient recruitment, biological sample collection, and biobank infrastructure to multi-center studies on disease prevention, early detection, and modification. Their clinical setting gives them direct access to newly diagnosed pediatric T1D patients — a critical and hard-to-recruit population for longitudinal research. They bring hands-on clinical expertise to translational research programs connecting laboratory science to real-world patient outcomes.

What they specialise in

How they've shifted over time

In the first INNODIA project (2015–2023), HKA's involvement centered on building infrastructure: biobanking, clinical sample networks, early detection, and prevention — the foundational data and sample collection layer of a large multi-center trial. By the time INNODIA HARVEST launched (2020–2024), the focus had visibly shifted toward depth of scientific understanding — microbiome, immunology, beta-cell function, disease mechanisms — alongside more sophisticated trial design concepts like master-protocols and patient-voice integration. This trajectory suggests HKA grew from a sample-contributing clinical site into a more analytically engaged partner, contributing not just patients and samples but insight into disease mechanisms and trial strategy.

HKA is deepening its scientific engagement in T1D beyond clinical sample provision — moving toward immunology, microbiome research, and adaptive trial design — making them increasingly relevant to precision medicine and next-generation therapeutic trial consortia.

How they like to work

HKA has participated exclusively as a consortium partner, never as coordinator, reflecting their role as a specialized clinical contributor rather than a project driver. They operate within large, multi-national consortia — 43 unique partners across 16 countries in just two projects — which indicates they are comfortable working within complex, well-organized research networks. This profile suits organizations looking for a credible, established German pediatric clinical site rather than a project management hub.

HKA has built a network of 43 unique partners across 16 countries through just two projects, entirely within the INNODIA research family. Their connections are concentrated in the European T1D clinical research community rather than spread across sectors.

What sets them apart

HKA occupies a specific and valuable niche: a German private pediatric hospital with a track record in multi-center EU clinical trials on type 1 diabetes. This combination — clinical access to newly diagnosed children, GCP-compliant trial infrastructure, and established INNODIA network membership — is not easily replicated by university hospitals or general research institutes. For any consortium targeting pediatric T1D patient cohorts in Germany, HKA offers both the clinical credibility and the existing network relationships to contribute meaningfully from day one.

Highlights from their portfolio

• INNODIA
  The flagship project — 8 years in duration with €678k in EC funding — placing HKA within one of Europe's largest translational T1D research consortia, covering the full pipeline from biobanking to clinical trial design.
• INNODIA HARVEST
  A direct continuation building on INNODIA's infrastructure, this project introduced more advanced themes including microbiome, immunology, and patient-voice, showing HKA's sustained and evolving commitment to the research program.